Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro Chantal EtievantJean-Marc BarretBridget T. Hill OriginalPaper Pages: 3 - 17
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies Howard A. Burris IIIEric RaymondDaniel D. Von Hoff OriginalPaper Pages: 19 - 27
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy Avi I. EinzigPeter H. WiernikValiant Tan OriginalPaper Pages: 29 - 36
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors Nancy W. PeacockHoward A. BurrisDaniel D. Von Hoff OriginalPaper Pages: 37 - 43
Phase I study of DMP 840 in pediatric patients with refractory solid tumors Joyce ThompsonCharles B. PrattAlberto Pappo OriginalPaper Pages: 45 - 49
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion Gladys I. RodriguezJohn G. KuhnDaniel D. Von Hoff OriginalPaper Pages: 57 - 67
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy Martin J. EdelmanDavid R. GandaraFrederick Meyers OriginalPaper Pages: 69 - 75
A phase II study of Temozolomide in advanced untreated pancreatic cancer Malcolm J. MooreRon FeldLillian L. Siu OriginalPaper Pages: 77 - 79
Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer Charles M. HaskellEvelyn MendozaRobert A. Figlin OriginalPaper Pages: 81 - 85
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas Shreyaskumar R. PatelM. Andrews BurgessRobert S. Benjamin OriginalPaper Pages: 87 - 92
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma Mark M. ZalupskiAnthony F. ShieldsVainutis Vaitkevicius OriginalPaper Pages: 93 - 96